Results 211 to 220 of about 62,672 (281)

Amoxicillin-Clavulanate-Induced Pityriasis Rosea: A Pharmacovigilance Case Report. [PDF]

Cureus
Franz C, Handa D, Joseph G, Bhatti N, Badyal DK.   +4 more
europepmc   +1 more source

Pharmacovigilance [PDF]

, 2020
openaire   +1 more source

No Evidence of Moderated Impulsivity Following Administration of the IMPase Inhibitor Ebselen in Healthy Adults

Human Psychopharmacology: Clinical and Experimental, Volume 41, Issue 3, May 2026.
ABSTRACT Objective Impulsivity is a transdiagnostic risk factor for numerous health morbidities and is strongly associated with early relapse and poor treatment outcomes in addictions and mood‐disorders. Lithium carbonate can be helpful in moderating the impulsive behaviors associated with mania, possibly mediated by reduced myo‐inositol activity ...
Matthew P. G. John, Luke Earnshaw, Nikhil Gauri Shankar, Jawad Sultan Raja, Timothy J. Davies, Phillip J. Cowen, Trevor Sharp, Alberto Salmoiraghi, Robert D. Rogers   +8 more
wiley   +1 more source

Safety profile and signal detection of tadalafil: a real-world analysis based on the Food and Drug adverse event reporting system. [PDF]

Sex Med
Li J, Li K, Yang S, Chen Y, Ren P, Deng G, Lei L, Ma Q, Yang H, Deng L.   +9 more
europepmc   +1 more source

The Effect of Iclepertin on Hematological Parameters: An Overview of Nonclinical Studies and Clinical Trials in Healthy Volunteers and Patients with Cognitive Impairment Associated with Schizophrenia

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract There are currently no approved pharmacotherapies to treat cognitive impairment associated with schizophrenia (CIAS). Iclepertin (BI 425809) is a selective glycine transporter‐1 (GlyT1) inhibitor that was investigated for the treatment of CIAS.
Peter Nagy, Justin Corey Fowler, Holger Rosenbrock, Wenbo Tang, Eric Fu, Annie Fraser, Holly Dursema, Julia Schlichtiger, Michael Desch, Fredrik Gruenenfelder   +9 more
wiley   +1 more source

Tokenization techniques for privacy-preserving healthcare data: tokenization nuts and bolts. [PDF]

Front Drug Saf Regul
Cook CV.
europepmc   +1 more source

The EUROmediCAT Network and Databases: A Resource for Pharmacovigilance in Pregnancy

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Background The evidence gap relating to the risk of congenital anomalies (CA) associated with first trimester medication exposure in pregnancy is well recognized. Aims We describe the EUROmediCAT network and databases, and the methodological approach to pregnancy pharmacovigilance.
Helen Dolk, Christine Damase‐Michel, Joan Morris, Amanda Neville, Ester Garne, Sue Jordan, Anke Rissmann, Alessio Coi, Deirdre Folan, Dieuwke Broekstra, Jennifer M. Broughan, Lea Bruneau, Clara Cavero‐Carbonell, Elly den Hond, Miriam Gatt, Mika Gissler, Babak Khoshnood, Anna Latos Bielenska, Hedvig Nordeng, Ljubica Odak, Mary O'Mahony, Isabelle Perthus, J. Luke Richardson, Florence Rouget, Joanna Sichitiu, David Tucker, Natalya Zymak‐Zakutnya, Maria Loane   +27 more
wiley   +1 more source

Atorvastatin-Associated Liver Injury: Outcome After Statin Rechallenge. [PDF]

Fundam Clin Pharmacol
Bertin B, Lacotte V, Cracowski JL, Gaiffe A, Dumortier J, Vial T.   +5 more
europepmc   +1 more source

Analysis of Mandatory Post‐Marketing Surveillance Studies Supports Revised Regulatory Requirements in Korea

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Purpose The objective of this analysis was to determine the contribution to the understanding of product benefit/risk made by non‐randomized, observational post‐marketing surveillance (PMS) studies previously required by the Ministry of Food and Drug Safety (MFDS) re‐examination system and conducted by Pfizer in Korea over 2000–2024. Methods A
Kevin Wolter, Seung‐Hee Jeong, Ju‐Won Woo, Eunsol Kim, Yoosun Lee, Sera Cha, Evelyn Moy, Rod Junor   +7 more
wiley   +1 more source